期刊文献+

膀胱移行细胞癌中淋巴管生长因子-D表达的研究

Research on the Expression of Vascular Endothelial Growth Factor-D in Bladder Transitional Cell Carcinoma
下载PDF
导出
摘要 【目的]探讨淋巴管生长因子D(VEGF—D)在膀胱移行细胞癌(BTCC)中的表达情况与患者预后的关系。【方法】采用免疫组化研究50例BTCC中VEGFD蛋白表达的水平,评估VEGF-D表达与患者临床病理资料的相关性。【结论]50例中VEGF—D阳性表达率84.0%;VEGF-D阳性表达与肿瘤分级、分期及大小明显相关(P〈0.05)、与复发性无关(P〉0.05)。【结论】在BTCC中,VEGF-D表达水平明显增强且与病理分级、临床分期及肿瘤大小呈正相关,其可能成为诊断和判定预后的一个指标及一项新的治疗靶点。 [Objective]To investigate the expression and clinical significance of vascular endothelial growth factor-D(VEGF-D) in bladder transitional cell carcinoma(BTCC). [Methods] The expression of VEGF-D in 50 BTCC was detected by immunohistochemistry. The relationship between VEGF-D expression and clinico pathological parameters was assessed. [Results]VEGF D expression was identified in 42 cases (84%). Higher expression of VEGF-D was significantly correlated with poor histological grade, clinical stage and tumor size ( P〈0.05), but not related with relapse( P〉0. 05). [Conclusion]There is positive correlation between the increased expression of VEGF and pathological grade, clinical stage and tumor size of patients with BTCC. It may be a novel biomarker and treatment target for the diagnosis and prognosis of BTCC.
出处 《医学临床研究》 CAS 2010年第1期75-77,共3页 Journal of Clinical Research
关键词 移行性细胞/病理学 膀胱肿瘤/病理学 淋巴因子 carcinoma,transitional/PA bladder neoplasms/PA lymphokines
  • 相关文献

参考文献1

二级参考文献20

  • 1Partanen T A, Alitalo K, Miettinen M. Lack of lymphatic vascular specificity of vascular endothelial growth factor receptor 3 in 185 vascular tumors [J]. Cancer, 1999,86(11):2406-2412.
  • 2Partanen T A, Arola J, Saaristo A, et al. VEGF-C and VEGF-D expression in neuroendocrine cells and the irreceptor, VEGFR-3, in fenestrated blood vessels in human tissues [J]. FASEB J, 2000, 14(13) :2087-2096.
  • 3Saaristo A, Partanen T A, Arola J, et al. Vascular endothelial growth factor-C and its receptor VEGFR-3 in the nasal mucosa and in nasopharyngeal tumors [J]. Am J Pathol, 2000, 157( 1 ) :7-14.
  • 4Skobe M, Brown L F, Tognazzi K, et al. Vascular endothelial growth factor-C (VEGF-C) and its receptors KDR and fit-4 are expressed in AIDS-associated Kaposi's sarcoma[J]. J Invest Dermatol, 1999,113(6) : 1047-1053.
  • 5Weidner N. Current pathologic methods for measuring intratumoral microvessel density within breast carcinoma and other solid tumors [J]. Breast Cancer Res Treat, 1995,36(2) : 169-180.
  • 6Veikkola T, Alitalo K. VEGFs, receptors and angiogenesis[J]. Semin Cancer Biol, 1999,9(3) :211-220.
  • 7Strauss L, Volland D, Kunkel M, et al. Dual role of VEGF family members in the pathogenesis of head and neck cancer(HNSCC): possible link between angiogenesis and immune toIerance[J]. Med Sci Monit, 2005,11(8) :280-292.
  • 8O-charoenrat P, Rhys-Evans P, Eccles S A. Expression of vascular endothelial growth factor family members in head and neck squamous cell carcinoma correlates with lymph node metastasis [J]. Cancer, 2001,92(3) :556-568.
  • 9Joukov V, Pajusola K, Kaipainen A, et al. A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4(VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases[J].EMBO J, 1996, 15(2):290-298.
  • 10Bevacqua S J, Welch D R, Diez de Pinos S M, et al.Quantitation of human melanoma, carcinoma and sarcoma tumor cell adhesion to lymphatic endothelium [ J ].Lymphology, 1990,23( 1 ) :4-14.

共引文献21

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部